Krystal Biotech (NASDAQ:KRYS) Upgraded to Strong-Buy at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities research analysts also recently weighed in on KRYS. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Weiss Ratings upgraded Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday. Evercore reissued an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, Bank of America increased their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $361.56.

Krystal Biotech Stock Up 0.3%

Shares of KRYS opened at $325.78 on Monday. The stock has a market cap of $9.64 billion, a PE ratio of 40.82 and a beta of 0.53. The business has a 50-day simple moving average of $340.79 and a two-hundred day simple moving average of $297.13. Krystal Biotech has a 12-month low of $132.31 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, equities research analysts expect that Krystal Biotech will post 7.27 EPS for the current year.

Insider Buying and Selling

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the transaction, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 26,642 shares of company stock valued at $8,243,923. Company insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. Handelsbanken Fonder AB boosted its position in Krystal Biotech by 58.4% in the fourth quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after purchasing an additional 39,000 shares during the last quarter. Fisher Asset Management LLC purchased a new position in shares of Krystal Biotech during the 4th quarter valued at $933,000. Biondo Investment Advisors LLC boosted its stake in shares of Krystal Biotech by 31.3% in the fourth quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after acquiring an additional 16,245 shares during the period. Principal Financial Group Inc. grew its holdings in Krystal Biotech by 15.6% during the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after buying an additional 22,231 shares in the last quarter. Finally, William Blair Investment Management LLC grew its stake in Krystal Biotech by 152.1% during the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock valued at $92,783,000 after acquiring an additional 227,038 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.